Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Biologic markers of chronic GVHD

Abstract

Biologic markers of chronic GVHD may provide insight into the pathogenesis of the syndrome, identify molecular targets for novel interventions, and facilitate advances in clinical management. Despite extensive work performed to date largely focused on prediction and diagnosis of the syndrome, little synthesis of findings and validation of promising candidate markers in independent populations has been performed. Studies suggest that risk for subsequent chronic GVHD development may be associated with donor–recipient genetic polymorphism, deficiency in regulatory immune cell populations (NK, Treg, DC2), and variation in inflammatory and immunoregulatory mediators post-HCT (increased TNFα, IL-10 and BAFF, and decreased TGFβ and IL-15). Established chronic GVHD is associated with alteration in immune cell populations (increased CD3+ T cells, Th17, CD4+ and CD8+ effector memory cells, monocytes, CD86 expression, BAFF/B cell ratio, and deficiency of Treg, NK cells, and naïve CD8+ T cells). Inflammatory and immunomodulatory factors (TNFα, IL-6, IL-1β, IL-8, sIL-2R, and IL-1Ra, BAFF, anti-dsDNA, sIL-2Rα, and sCD13) are also perturbed. Little is known about biologic markers of chronic GVHD phenotype and severity, response to therapy, and prognosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bertinetto FE, Dall'Omo AM, Mazzola GA, Rendine S, Berrino M, Bertola L et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int J Immunogenet 2006; 33: 375–384.

    Article  CAS  Google Scholar 

  2. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A . Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2005; 90: 425–426.

    CAS  PubMed  Google Scholar 

  3. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG . Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001; 98: 1594–1600.

    Article  CAS  Google Scholar 

  4. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG . Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2003; 122: 778–787.

    Article  CAS  Google Scholar 

  5. Kim DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 2005; 79: 1615–1622.

    Article  CAS  Google Scholar 

  6. Laguila Visentainer JE, Lieber SR, Lopes Persoli LB, Dutra Marques SB, Vigorito AC, Penteado Aranha FJ et al. Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine 2005; 32: 171–177.

    Article  CAS  Google Scholar 

  7. Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes T et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation 2004; 77: 587–596.

    Article  CAS  Google Scholar 

  8. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva Jr WA, Latouche A et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908–3918.

    Article  CAS  Google Scholar 

  9. Sivula J, Turpeinen H, Volin L, Partanen J . Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunol 2009; 10: 24.

    Article  Google Scholar 

  10. Takahashi H, Furukawa T, Hashimoto S, Suzuki N, Kuroha T, Yamazaki F et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 1317–1323.

    Article  CAS  Google Scholar 

  11. Viel DO, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, Vigorito AC et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 2007; 66: 703–710.

    Article  CAS  Google Scholar 

  12. Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snavely J, Chen H et al. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 2011; 118: 1140–1144.

    Article  CAS  Google Scholar 

  13. Fore M, Jagasia M, Sarantopoulos S, Richards KL . Further examination of BAFF SNPs in cGVHD. Blood 2012; 120: 700–701.

    Article  CAS  Google Scholar 

  14. Ambruzova Z, Mrazek F, Raida L, Stahelova A, Faber E, Indrak K et al. Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation. Hum Immunol 2009; 70: 457–460.

    Article  CAS  Google Scholar 

  15. Arora M, Lindgren B, Basu S, Nagaraj S, Gross M, Weisdorf D et al. Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia 2010; 24: 1470–1475.

    Article  CAS  Google Scholar 

  16. Boukouaci W, Busson M, Peffault de Latour R, Rocha V, Suberbielle C, Bengoufa D et al. MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. Blood 2009; 114: 5216–5224.

    Article  CAS  Google Scholar 

  17. Broen K, van der Waart AB, Greupink-Draaisma A, Metzig J, Feuth T, Schaap NP et al. Polymorphisms in CCR6 are associated with chronic graft-versus-host disease and invasive fungal disease in matched-related hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1443–1449.

    Article  CAS  Google Scholar 

  18. Inamoto Y, Murata M, Katsumi A, Kuwatsuka Y, Tsujimura A, Ishikawa Y et al. Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone Marrow Transplant 2010; 45: 363–369.

    Article  CAS  Google Scholar 

  19. Kornblit B, Masmas T, Petersen SL, Madsen HO, Heilmann C, Schejbel L et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 239–252.

    Article  CAS  Google Scholar 

  20. McGuirk J, Hao G, Hou W, Abhyankar S, Williams C, Yan W et al. Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation. J Hematol Oncol 2009; 2: 17.

    Article  Google Scholar 

  21. Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A . Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 2010; 115: 2319–2328.

    Article  CAS  Google Scholar 

  22. Shimada M, Onizuka M, Machida S, Suzuki R, Kojima M, Miyamura K et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br J Haematol 2007; 139: 458–463.

    CAS  PubMed  Google Scholar 

  23. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201–2210.

    Article  CAS  Google Scholar 

  24. Kim DH, Sohn SK, Lee NY, Baek JH, Kim JG, Won DI et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol 2005; 75: 299–308.

    Article  Google Scholar 

  25. Larghero J, Rocha V, Porcher R, Filion A, Ternaux B, Lacassagne MN et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol 2007; 138: 101–109.

    Article  Google Scholar 

  26. Li Q, Zhai Z, Xu X, Shen Y, Zhang A, Sun Z et al. Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation. Leuk Res 2010; 34: 1158–1168.

    Article  CAS  Google Scholar 

  27. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004; 104: 2187–2193.

    Article  CAS  Google Scholar 

  28. Morariu-Zamfir R, Rocha V, Devergie A, Socie G, Ribaud P, Esperou H et al. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001; 27: 575–580.

    Article  CAS  Google Scholar 

  29. Rajasekar R, Mathews V, Lakshmi KM, Sellathamby S, George B, Viswabandya A et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol Blood Marrow Transplant 2008; 14: 344–350.

    Article  Google Scholar 

  30. Rocha V, Carmagnat MV, Chevret S, Flinois O, Bittencourt H, Esperou H et al. Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. Exp Hematol 2001; 29: 1347–1352.

    Article  CAS  Google Scholar 

  31. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant 2009; 44: 729–737.

    Article  CAS  Google Scholar 

  32. Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001; 97: 2948–2956.

    Article  CAS  Google Scholar 

  33. Yamasaki S, Henzan H, Ohno Y, Yamanaka T, Iino T, Itou Y et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 2003; 32: 505–510.

    Article  CAS  Google Scholar 

  34. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226–4235.

    CAS  PubMed  Google Scholar 

  35. Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 822–828.

    Article  CAS  Google Scholar 

  36. Ukena SN, Grosse J, Mischak-Weissinger E, Buchholz S, Stadler M, Ganser A et al. Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells. Ann Hematol 2011; 90: 213–218.

    Article  CAS  Google Scholar 

  37. Ritchie D, Seconi J, Wood C, Walton J, Watt V . Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 706–712.

    Article  CAS  Google Scholar 

  38. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007; 13: 6107–6114.

    Article  CAS  Google Scholar 

  39. Pratt LM, Liu Y, Ugarte-Torres A, Hoegh-Petersen M, Podgorny PJ, Lyon AW et al. IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. Bone Marrow Transplant 2013; 48: 722–728.

    Article  CAS  Google Scholar 

  40. Shimura K, Ashihara E, Shimazaki C, Matsunaga S, Taniguchi K, Uchiyama H et al. Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 426–437.

    Article  Google Scholar 

  41. Mattsson J, Remberger M, Andersson O, Sundberg B, Nord M . Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. Transplantation 2005; 79: 1411–1416.

    Article  CAS  Google Scholar 

  42. Abrahamsen IW, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord GE . Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica 2005; 90: 86–93.

    PubMed  Google Scholar 

  43. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andre V et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009; 88: 1261–1272.

    Article  CAS  Google Scholar 

  44. D'Asaro M, Dieli F, Caccamo N, Musso M, Porretto F, Salerno A . Increase of CCR7- CD45RA+ CD8 T cells (T(EMRA)) in chronic graft-versus-host disease. Leukemia 2006; 20: 545–547.

    Article  CAS  Google Scholar 

  45. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT et al. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood 2004; 103: 3986–3988.

    Article  CAS  Google Scholar 

  46. Arpinati M, Chirumbolo G, Marzocchi G, Baccarani M, Rondelli D . Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. Transplantation 2008; 85: 1826–1832.

    Article  CAS  Google Scholar 

  47. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 386–397.

    Article  CAS  Google Scholar 

  48. D'Orsogna LJ, Wright MP, Krueger RG, McKinnon EJ, Buffery SI, Witt CS et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells. Biol Blood Marrow Transplant 2009; 15: 795–803.

    Article  CAS  Google Scholar 

  49. Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 208–219.

    Article  Google Scholar 

  50. Kuzmina Z, Greinix HT, Weigl R, Kormoczi U, Rottal A, Frantal S et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood 2011; 117: 2265–2274.

    Article  CAS  Google Scholar 

  51. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865–3874.

    Article  CAS  Google Scholar 

  52. Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012; 120: 2529–2536.

    Article  CAS  Google Scholar 

  53. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004; 103: 2410–2416.

    Article  CAS  Google Scholar 

  54. Barak V, Levi-Schaffer F, Nisman B, Nagler A . Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 1995; 17: 169–173.

    Article  CAS  Google Scholar 

  55. Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M . Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma 1997; 28: 159–169.

    Article  CAS  Google Scholar 

  56. Liem LM, van Houwelingen HC, Goulmy E . Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 66: 863–871.

    Article  CAS  Google Scholar 

  57. Poloni A, Sartini D, Emanuelli M, Trappolini S, Mancini S, Pozzi V et al. Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. Cytokine 2011; 53: 376–383.

    Article  CAS  Google Scholar 

  58. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, Noto S et al. Th2 cytokines (IL-4, IL-10 and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood mononuclear cells during chronic graft-versus-host disease. Eur J Haematol 1996; 57: 111–113.

    Article  CAS  Google Scholar 

  59. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111: 3276–3285.

    Article  CAS  Google Scholar 

  60. Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. Biol Blood Marrow Transplant 2011; 17: 1804–1813.

    Article  CAS  Google Scholar 

  61. Ivison SKA, Storer B, McMaster R, Hansen J, Lee SJ, Schultz K . Soluble Aminopeptidase N (CD13) is a Promising Diagnostic Biomarker of Late-Onset Chronic Graft vs Host Disease in Adults. (abstract). In:. BMT Tandem Meetings. Salt Lake City, UT, USA, 2013.

    Google Scholar 

  62. Kitko CCD, Levine J, Martin P, Flowers M, Hansen J, Chang L et al. MIG: a plasma chronic GVHD biomarkers that is diagnostic at onset and associated with disease severity. (abstract). In:. EBMT. London, UK, 2013.

    Google Scholar 

  63. Kohrt HE TL, Li L, Alizadeh A, Hsieh S, Strober S, Sarwal M et al. Identification of candidate transcriptional biomarkers associated with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. (abstract). In:. American Society of Hematology - Annual Meeting and Exposition. Atlanta, GA, USA, 2012.

    Google Scholar 

  64. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237–241.

    Article  CAS  Google Scholar 

  65. Lai P, Weng J, Lu Z, Guo R, Luo C, Wu S et al. Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease. DNA Cell Biol 2011; 30: 1019–1025.

    Article  CAS  Google Scholar 

  66. Boutin M, Ahmad I, Jauhiainen M, Lachapelle N, Rondeau C, Roy J et al. NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. Anal Chem 2009; 81: 9454–9461.

    Article  CAS  Google Scholar 

  67. Westekemper H, Meller S, Citak S, Schulte C, Steuhl KP, Homey B et al. Differential chemokine expression in chronic GVHD of the conjunctiva. Bone Marrow Transplant 2010; 45: 1340–1346.

    Article  CAS  Google Scholar 

  68. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT . Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113: 3620–3630.

    Article  CAS  Google Scholar 

  69. Kuzmina Z, Krenn K, Petkov V, Kormoczi U, Weigl R, Rottal A et al. CD19+CD21low B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood 2013; 121: 1886–1895.

    Article  CAS  Google Scholar 

  70. Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011; 117: 2275–2283.

    Article  CAS  Google Scholar 

  71. Greinix HT, Fae I, Schneider B, Rosenmayr A, Mitterschiffthaler A, Pelzmann B et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant 2005; 35: 57–62.

    Article  CAS  Google Scholar 

  72. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    Article  CAS  Google Scholar 

  73. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200–4206.

    Article  CAS  Google Scholar 

  74. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007; 13: 315–328.

    Article  CAS  Google Scholar 

  75. Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007; 137: 142–151.

    Article  Google Scholar 

  76. Spellman S, Klein J, Haagenson M, Askar M, Baxter-Lowe LA, He J et al. Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 739–746.

    Article  Google Scholar 

  77. Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, Wang T . Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. Blood 2013; 121: 1896–1905.

    Article  CAS  Google Scholar 

  78. Gallardo D, Arostegui JI, Balas A, Torres A, Caballero D, Carreras E et al. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation. Br J Haematol 2001; 114: 931–936.

    Article  CAS  Google Scholar 

  79. Grumet FC, Hiraki DD, Brown BWM, Zehnder JL, Zacks ES, Draksharapu A et al. CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant 2001; 7: 503–512.

    Article  CAS  Google Scholar 

  80. Spellman S, Warden MB, Haagenson M, Pietz BC, Goulmy E, Warren EH et al. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2009; 15: 856–863.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by (NCI) CA 118953 (PI: Stephanie J Lee) and CA163438 (PI: Stephanie J Lee).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Pidala.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pidala, J., Sarwal, M., Roedder, S. et al. Biologic markers of chronic GVHD. Bone Marrow Transplant 49, 324–331 (2014). https://doi.org/10.1038/bmt.2013.97

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.97

Keywords

This article is cited by

Search

Quick links